The modulation of skeletal muscle glycosylation as a potential therapeutic intervention in muscular dystrophies

Acta Myologica

Volumn 24, Issue 3, 2005, Pages 217-221

  Brockington, M ^a   Muntoni, Francesco ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Imperial College Hammersmith Hospital Campus   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DYSTROGLYCAN; SCLEROPROTEIN;

ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; GLYCOSYLATION; MUSCULAR DYSTROPHY; SARCOLEMMA; SKELETAL MUSCLE; T LYMPHOCYTE;

DYSTROGLYCANS; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33645337097     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Angelini C. Limb-girdle muscular dystrophies: heterogeneity of clinical phenotypes and pathogenetic mechanisms. Acta Myol 2004;23:130-6.
2. Laval SH, Bushby KM. Limb-girdle muscular dystrophies-from genetics to molecular pathology. Neuropathol Appl Neurobiol 2004;30:91-105.
3. Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord 2004;14:635-49.
4. Henry MD, Campbell KP. Dystroglycan: an extracellular matrix receptor linked to the cytoskeleton. Curr Opin Cell Biol 1996;8:625-31.
5. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 1999;11:602-7.
6. Michele DE, Campbell, K.P. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem 2003;278:15457-60.
7. Durbeej M, Henry MD, Campbell KP. Dystroglycan in development and disease. Curr Opin Cell Biol 1998;10:594-601.
8. Endo T. O-mannosyl glycans in mammals. Biochim Biophys Acta 1999;1473:237-46.
9. Endo T, Toda T. Glycosylation in congenital muscular dystrophies. Biol Pharm Bull 2003;26:1641-7.
10. Hewitt JE, Grewal PK. Glycosylation defects in inherited muscle disease. Cell Mol Life Sci 2003;60:251-8.
11. Martin PT. Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. Glycobiology 2003a;13:55R-66R.
12. Martin PT, Freeze HH. Glycobiology of neuromuscular disorders. Glycobiology 2003;13:67R-75R.
13. Martin PT. Glycobiology of the neuromuscular junction. J Neurocytol 2003b;32:915-29.
14. Xia B, Hoyte K, Kammesheidt A, et al. Overexpression of the CT GalNAc transferase in skeletal muscle alters myofiber growth, neuromuscular structure, and laminin expression. Dev Biol 2002;242:58-73.
15. Perkins KJ, Davies KE. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul Disord 2002;12 Suppl 1:78-89.
16. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol 2000;150:1209-14.
17. Amann KJ, Guo AW, Ervasti JM. Utrophin lacks the rod domain actin binding activity of dystrophin. J Biol Chem 1999;274:35375-80
18. Rybakova IN, Patel JR, Davies KE, Yurchenco PD, Ervasti JM. Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. Mol Biol Cell 2002;13:1512-21.
19. Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A 2002;99:5616-21.
20. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005;62:809-23.
21. Muntoni F. Journey into muscular dystrophies caused by abnormal glycosylation. Acta Myol 2004;23:79-84.
22. Muntoni F, Brockington M, Torelli S, Brown SC. Defective glycosylation in congenital muscular dystrophies. Curr Opin Neurol 2004;17:205-9.
23. Grewal PK, Hewitt JE. Glycosylation defects: a new mechanism for muscular dystrophy? Hum Mol Genet 2003;12 Spec No 2:R259-64.
24. Manya H, Chiba A, Yoshida A, et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci U S A 2004;101:500-5.
25. Zhang W, Vajsar J, Cao P, et al. Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available reagents. Clin Biochem 2003;36:339-44.
26. Brown SC, Fassati A, Popplewell L, et al. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. J Cell Sci 1999;112 (Pt 2):209-16.
27. Michele DE, Barresi R, Kanagawa M, et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 2002;418:417-22.
28. Grewal PK, Holzfeind PJ, Bittner RE, Hewitt JE. Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat Genet 2001;28:151-4.
29. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDClD, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003;12:2853-61.
30. Brockington M, Torelli S, Prandini P, et al. Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy. Hum Mol Genet 2005;14:657-65.
31. Grewal PK, McLaughlan JM, Moore CJ, Browning CA, Hewitt JE. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology 2005;15:912-23.
32. Kanagawa M, Saito F, Kunz S, et al. Molecular recognition by LARGE is essential
33. Barresi R MD, Kanagawa M, Harper HA, et al. LARGE can functionally bypass alpha- for expression of functional dystroglycan. Cell 2004;117:953-64.
34. dystroglycan defects in distinct congenital muscular dystrophies. Nat Med 2004.